Satoyoshi syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:3130OMIM:600705M35.8
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Satoyoshi syndrome (also known as Satoyoshi disease or komuragaeri disease) is an extremely rare multisystem disorder of presumed autoimmune origin, first described by Eijiro Satoyoshi in 1978. The condition is characterized by progressive, painful intermittent muscle spasms (komuragaeri), alopecia universalis (complete hair loss), diarrhea or other gastrointestinal disturbances, and skeletal abnormalities including osteolytic lesions and short stature due to epiphyseal destruction. The muscle spasms typically begin in the legs and may spread to involve the trunk, arms, and masticatory muscles, often severely impairing mobility and quality of life. Secondary amenorrhea is frequently observed in affected females. Endocrine abnormalities, including glucose intolerance, may also be present. The disease predominantly affects children and adolescents, with onset typically occurring between the ages of 6 and 15 years. It appears to occur more frequently in females and has been reported predominantly in individuals of Japanese descent, though cases have been described in other ethnic groups worldwide. The pathogenesis is not fully understood, but an autoimmune mechanism is strongly suspected based on the presence of autoantibodies and the association with other autoimmune conditions in some patients. Treatment is primarily symptomatic and supportive. Muscle relaxants such as dantrolene sodium have been used with some success to control the painful spasms. Corticosteroids and other immunosuppressive therapies have shown benefit in some cases, supporting the autoimmune hypothesis. Bisphosphonates may be considered for skeletal involvement. Early treatment may help prevent progressive skeletal deformities. The prognosis is variable; while the condition can be debilitating, some patients respond well to treatment. No curative therapy currently exists, and long-term management requires a multidisciplinary approach involving neurology, rheumatology, endocrinology, and orthopedics.

Also known as:

Clinical phenotype terms— hover any for plain English:

Abnormal humerus morphologyHP:0031095Hypoplasia of the uterusHP:0000013Abnormality of the ovaryHP:0000137Abnormal joint morphologyHP:0001367Alopecia universalisHP:0002289
Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Childhood

Begins in childhood, roughly ages 1 to 12

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Satoyoshi syndrome.

View clinical trials →

No actively recruiting trials found for Satoyoshi syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Satoyoshi syndrome community →

No specialists are currently listed for Satoyoshi syndrome.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Satoyoshi syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Satoyoshi syndromeForum →

No community posts yet. Be the first to share your experience with Satoyoshi syndrome.

Start the conversation →

Latest news about Satoyoshi syndrome

No recent news articles for Satoyoshi syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Satoyoshi syndrome

What is Satoyoshi syndrome?

Satoyoshi syndrome (also known as Satoyoshi disease or komuragaeri disease) is an extremely rare multisystem disorder of presumed autoimmune origin, first described by Eijiro Satoyoshi in 1978. The condition is characterized by progressive, painful intermittent muscle spasms (komuragaeri), alopecia universalis (complete hair loss), diarrhea or other gastrointestinal disturbances, and skeletal abnormalities including osteolytic lesions and short stature due to epiphyseal destruction. The muscle spasms typically begin in the legs and may spread to involve the trunk, arms, and masticatory muscles

How is Satoyoshi syndrome inherited?

Satoyoshi syndrome follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Satoyoshi syndrome typically begin?

Typical onset of Satoyoshi syndrome is childhood. Age of onset can vary across affected individuals.